The interaction of ACE inhibitors and aspirin in heart failure: Torn between two lovers

American Heart Journal

Volumn 138, Issue 2 I, 1999, Pages 193-197

  Teerlink, J R ^a   Massie, B M ^a  

^a 111C San Francisco VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ANTICOAGULATION; DRUG CROSS REACTIVITY; DRUG MECHANISM; EDITORIAL; HEART FAILURE; HUMAN; HUMAN CELL; HUMAN TISSUE; MORTALITY; PRIORITY JOURNAL; THEORY;

EID: 0032796477     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70099-2     Document Type: Editorial

References (33)

1. Guazzi M, Pontone G, Agostoni P. Asprin worsens exercise performance and pulmonary gas exchange in patients with heart failure patients who are taking angiotensin-converting enzyme inhibitors. Am Heart J 1999;138:254-60.
2. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J 1991;121:1852-3.
3. Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rationale for preventive strategies and comprehensive disease management. Am Heart J 1997;133:703-12.
4. Teerlink JR. The evolving role of angiotensin-converting enzyme inhibition in heart failure: expanding the protective envelope. J Cardiovasc Pharmacol 1994;24(Suppl 3):S32-7.
5. ISIS-2 (Second International Study of Infarct Survival) collaborative group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
6. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. The ISIS-2 (Second International Study of Infarct Survival) collaborative group. BMJ 1998;316:1337-43.
7. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
8. Cleland JG, Bulpitt CJ, Falk RH, Findlay IN, Oakley CM, Murray G, et al. Is aspirin safe for patients with heart failure? Br Heart J 1995;74:215-9.
9. Goto S, Sakai H, Ikeda Y, Hande S. Arterial thrombosis in heart failure [letter]. Lancet 1998;351:1558-9.
10. Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995;47:25-49.
11. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-52.
12. Moroi M, Akatsuka N, Fukazawa M, Hara K, Ishikawa M, Aikawa J, et al. Endothelium-dependent relaxation by angiotensin-converting enzyme inhibitors in canine femoral arteries. Am J Physiol 1994;266:H583-9.
13. Evans MA, Burnett JC Jr, Redfield MM. Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. J Am Coll Cardiol 1995;25:1445-50.
14. Hartman JC, Hullinger TG, Wall TM, Shebuski RJ. Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition. Eur J Pharmacol 1993;234:229-36.
15. Hartman JC, Wall TM, Hullinger TG, Shebuski RJ. Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140. J Cardiovasc Pharmacol 1993;21:996-1003.
16. Kalkman EA, van Suylen RJ, van Dijk JP, Saxena PR, Schoemaker RG. Chronic aspirin treatment affects collagen deposition in non-infarcted myocardium during remodeling after coronary artery ligation in the rat. J Mol Cell Cardiol 1995;27:2483-94.
17. Stauss HM, Zhu YC, Redlich T, Adamiak D, Mott A, Kregel KC, et al. Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk 1994;1:255-62.
18. Stauss HM, Adamiak D, Zhu YC, Redlich T, Unger T. ACE inhibition following myocardial infarction (MI) in kinin-deficient Brown-Norway Katholiek rats (BNK). In: Council of High Blood Pressure Research, 48th Annual Fall Conference and Scientific Sessions, Sept 27-30, 1994; Chicago( IL): 1994.
19. Rose J, Ehring T, Sakka SG, Skyschally A, Heusch G. Aspirin does not prevent the attenuation of myocardial stunning by the ACE inhibitor ramiprilat. J Mol Cell Cardiol 1996;28:603-13.
20. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-55.
21. Nakamura M, Funakoshi T, Arakawa N, Yoshida H, Makita S, Hiramori K. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure. J Am Coll Cardiol 1994;24:1321-7.
22. Spaulding C, Charbonnier B, Cohen-Solal A, Juillière Y, Kromer EP, Benhamda K, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind, randomized comparative trial. Circulation 1998;98:757-65.
23. van Wijngaarden J, Smit AJ, de Graeff PA, van Gilst WH, van der Broek SA, van Veldhuisen DJ, et al. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1994;23:240-5.
24. Baur LH, Schipperheyn JJ, van der Laarse A, Souverijn JH, Frölich M, de Groot A, et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J 1995;73:227-36.
25. Jeserich M, Pape L, Just H, Hornig B, Kupfer M, Meunzel T, et al. Effect of long-term angiotensin-converting enzyme inhibition on vascular function in patients with chronic congestive heart failure. Am J Cardiol 1995;76:1079-82.
26. Riegger GA, Kahles HW, Elsner D, Kromer EP, Kochsiek K. Effects of acetylsalicylic acid on renal function in patients with chronic heart failure. Am J Med 1991;90:571-5.
27. Dietz R, Nagel F, Osterziel KJ. Angiotensin-converting enzyme inhibitors and renal function in heart failure. Am J Cardiol 1992;70:119C-25C.
28. Guazzi M, Marenzi G, Alimento M, Contini M, Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation 1997;95:1930-6.
29. Guazzi M, Melzi G, Agostoni P. Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1997;80:1572-6.
30. Guazzi M, Agostoni P. Decrease by ACE-inhibition of the excessive alveolar-capillary membrane resistance to gas transfer in chronic heart failure. Cardiologia 1998;43:625-30.
31. Oosterga M, Anthonio RL, de Kam PJ, Kingma JH, Crijns HJ, van Gilst WH. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol 1998;81:1178-81.
32. Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II CONSENSUS II. Am J Cardiol 1997;79:115-9.
33. Al-Khadra AS, Salem DN, Rand WM, Udelson JE, Smith JJ, Konstam MA. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J Am Coll Cardiol 1998;31:419-25.